YTS104 / BriSTAR Immunotech, Beijing Qingyi Taike Pharma - LARVOL DELTA

LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML (clinicaltrials.gov) - P1 | N=11 | Completed | Sponsor: Peking University People's Hospital | Trial primary completion date: Dec 2023 ➔ Aug 2024 | Not yet recruiting ➔ Completed

Trial completion • Trial primary completion date • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • LILRB4

LILRB4 Synthetic T-Cell Receptor and Antigen Receptor-T (STAR-T) for Refractory/Relapsed Acute Myeloid Leukemia: First-in-Human Phase I Clinical Trial (ASH 2024) - P1 | "Conclusion Our first-in-human study demonstrated that LILRB4 STAR-T therapy is a promising approach in LILRB4 -positive r/r AML patients, even in those who have undergone extensive prior treatments and experienced relapse post allo-HSCT. Further data from the phase II trial and longer follow-up time are essential."

Clinical • IO biomarker • P1 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • LILRB4

LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma. (PubMed, Haematologica) - "In conclusion, our study elucidates that LILRB4 is an ideal biomarker and promising immunotherapy target for high-risk MM. LILRB4-STAR-T cell immunotherapy is promising against tumor cells and immunosuppressive tumor microenvironment in MM."

IO biomarker • Journal • Tumor cell • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • LILRB4

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology • LILRB4

Development of LILRB4 biparatopic synthetic T-cell receptor and antigen receptor (STAR)-T cells for the treatment of acute myeloid leukemia (AML) (AACR 2023) - "Multiple STAR-T cells were generated using a lentiviral-based vector and tested for their tumor lysis activity. Among multiple nanobodies tested, two nanobodies that displayed high antigen binding affinity and specificity were identified for further studies. They recognized two distinctive epitopes of LILRB4, and neither of them had competitive binding with APOE or FN1, known ligands of LILRB4."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • APOE • STAR

LILRB4 STAR-T Cell Therapy for Monocytic Leukemia (clinicaltrials.gov) - P=N/A | N=10 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital

New trial • Acute Myelogenous Leukemia • Chronic Myeloid Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

BriSTAR Immunotech to Present at the BIO CEO & Investor Conference (PRNewswire) - "BriSTAR Immunotech...announced today that its Chief Executive Officer, James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference....Dr. Pan's presentation will focus on how BriSTAR's STAR-T platform is used to formulate novel cell therapy candidates that better address the challenges in treating solid tumors....Dr. Pan will also discuss the latest developments for the Company's novel T cell immunotherapy candidates, including lead candidates CD19/CD20 STAR-T and LILRB4 STAR-T. CD19/CD20 STAR-T is currently in clinical trials targeting relapsed/refractory B-cell non-Hodgkin lymphoma and LILRB4 STAR-T is indicated for acute myeloid leukemia (AML)."

Clinical data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology

BriSTAR Immunotech To Present its Novel Cell Therapy for Acute Myeloid Leukemia at the AACR Special Conference on AML and MDS (PRNewswire) - "BriSTAR...announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at the American Association for Cancer Research (AACR) special conference on acute myeloid leukemia and myelodysplastic syndrome, taking place January 23-25, 2023, in Austin, Texas.'The data shows that our LILRB4 STAR-T cell therapy exhibits potent anti-tumor activity against AML in preclinical models,' said Dr. James Pan, CEO at BriSTAR Immunotech. 'These findings support our strategy to maximize the potential of our unique STAR-T technology platform.'"

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Peking University People's Hospital

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology